Biosimilar Enbrel: Sandoz, FDA Panel Bring Experience To TNF-Inhibitor Review
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Arthritis Advisory Committee will discuss Sandoz’s 351(k) application referencing Amgen's etanercept July 13.
You may also be interested in...
Sandoz Steers Enbrel Biosimilar Away From Equivalence Quandary With Reanalysis
FDA says Sandoz's biosimilar is highly similar to Amgen's Enbrel after Sandoz answered question about data comparing it to US-approved product.
Sandoz Steers Enbrel Biosimilar Away From Equivalence Quandary With Reanalysis
FDA says Sandoz's biosimilar is highly similar to Amgen's Enbrel after Sandoz answered question about data comparing it to US-approved product.
Biosimilars: Does FDA Caution Make Advisory Committee A Rubber Stamp?
Like biosimilar candidates Zarxio and Inflectra before it, Amgen's ABP 501 enters its advisory committee review with FDA's full-throated endorsement.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: